View all veterinary jobs
The Nu.Q Canine Cancer Test is a new technology that measures circulating nucleosomes in order to enable earlier cancer detection in some of the most common types of canine cancers.
According to the company, Nu.Q testing requires only 50µL of EDTA plasma from a patient and provides accurate results in 5 to 10 minutes.
One study demonstrated >75% detection rates for common cancers in dogs like lymphoma and hemangiosarcoma when using Nu.Q1.
The company suggests veterinary professionals use the tool during annual check-ups or regular senior wellness exams for older dogs and at-risk breeds.
Jimmy Barr, DVM, DACVECC, Chief Medical Officer at Antech, said: “It’s exciting to see innovations like Nu.Q Canine Cancer Test become more widely available to veterinary teams in Europe.
"With cancer affecting one in four dogs2, it is critical that veterinary professionals have access to fast and accurate cancer screening methods, so they can make informed and timely decisions and ultimately change pet health outcomes.
https://antechdiagnostics.co.uk
References
This adds to the company's existing lab network, which also includes Southfields Veterinary Specialists Diagnostic Laboratory and the Dick White Referrals Diagnostic Laboratory.
In addition to its lab services, the company also offers in-house diagnostics, imaging and technology solutions, telemedicine services and rapid diagnostics.
In the UK, the company will offer KeyScreen, a DNA-based GI parasite screening solution, AIS RapidRead, an imaging technology that enables diagnosis in under ten minutes, and coming soon, Nu.Q, a system that measures nucleosomes to screen and monitor for canine cancer.
Antech will be at the London Vet Show this year, where veterinary teams will have the chance to hear from the company's head of clinical pathology, Dr Butty Villiers and head of anatomic pathology, Dr Rachel Pittaway, about the latest innovations and diagnostics developments.
antechdiagnostics.com